InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| RAW-Blue™ Cells | Photothermal immunotherapy of melanoma using TLR-7 agonist laden tobacco mosa... | 2022 | Nanomedicine | Nkanga C.I. et al. | DOI: 10.1016/j.nano.2022.102573 |
| Puromycin | Glucocorticoids enhance chemotherapy-driven stress granule assembly and impai... | 2022 | J Cell Sci. | Schwed-Gross A. et al. | DOI: 10.1242/jcs.259629 |
| Normocin® - Antimicrobial Reagent | A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and d... | 2022 | Sci Adv. | Tanton H. et al. | DOI: 10.1126/sciadv.abm3108 |
| Primocin® | A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and d... | 2022 | Sci Adv. | Tanton H. et al. | DOI: 10.1126/sciadv.abm3108 |
| Poly(I:C) (HMW) VacciGrade™ | An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine... | 2022 | PNAS Nexus | Sui Y. et al. | DOI: 10.1093/pnasnexus/pgac091 |
| Normocin® - Antimicrobial Reagent | dCas9-mediated dysregulation of gene expression in human induced pluripotent ... | 2022 | Metab Eng. | Haellman V. et al. | DOI: 10.1016/j.ymben.2022.06.003 |
| Puromycin | dCas9-mediated dysregulation of gene expression in human induced pluripotent ... | 2022 | Metab Eng. | Haellman V. et al. | DOI: 10.1016/j.ymben.2022.06.003 |
| Puromycin | MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negati... | 2022 | Commun Biol. | Turco C. et al. | DOI: 10.1038/s42003-022-03539-x |
| Alhydrogel® adjuvant 2% | Neuraminidase (NA) 370-Loop Mutations of the 2009 Pandemic H1N1 Viruses Affec... | 2022 | Viruses | Chen T.H. et al. | DOI: 10.3390/v14061304 |
| Alhydrogel® adjuvant 2% | Production of Neuraminidase Virus Like Particles by Stably Transformed Insect... | 2022 | Mol Biotechnol. | Khanefard N. et al. | DOI: 10.1007/s12033-022-00519-8 |
| AddaVax™ | Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adju... | 2022 | Clin Exp Vaccine Res. | Mazumder S. et al. | DOI: 10.7774/cevr.2022.11.2.163 |
| Plasmocin® - Mycoplasma Elimination Reagent | Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV... | 2022 | Nat Microbiol. | Uraki R. et al. | DOI: 10.1038/s41564-022-01170-4 |
| G418 (Geneticin) | Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV... | 2022 | Nat Microbiol. | Uraki R. et al. | DOI: 10.1038/s41564-022-01170-4 |
| Jurkat Reporter Cells (NFAT) | Arginine-based cationic liposomes accelerate T cell activation and differenti... | 2022 | Int J Pharm. | Li T. et al. | DOI: 10.1016/j.ijpharm.2022.121917 |
| pDRIVE-Survivin | Development of a cancer cells self‑activating and miR‑125a‑5p expressing poly... | 2022 | Int J Mol Med. | Chang Y.C. et al. | DOI: 10.3892/ijmm.2022.5158 |
| Normocin® - Antimicrobial Reagent | Protocol to isolate and assess spike protein cleavage in SARS-CoV-2 variants ... | 2022 | STAR Protoc. | Escalera A. et al. | DOI: 10.1016/j.xpro.2022.101502 |
| Puromycin | Protocol to isolate and assess spike protein cleavage in SARS-CoV-2 variants ... | 2022 | STAR Protoc. | Escalera A. et al. | DOI: 10.1016/j.xpro.2022.101502 |
| Puromycin | A simulation model of heterochromatin formation at submolecular detail. | 2022 | iScience | Williams M.R. et al. | DOI: 10.1016/j.isci.2022.104590 |
| Blasticidin | A simulation model of heterochromatin formation at submolecular detail. | 2022 | iScience | Williams M.R. et al. | DOI: 10.1016/j.isci.2022.104590 |
| Puromycin | Functional genomics screening identifies aspartyl-tRNA synthetase as a novel ... | 2022 | J Pathol. | Liu B. et al. | DOI: 10.1002/path.5980 |